News

Arginine Therapy May Alleviate PH in Thalassemia Patients

The amino acid arginine may contribute to pulmonary hypertension in patients with thalassemia, a disorder that leads to abnormal oxygenation of blood. A team of researchers from the Thalassemia Clinical Research Network conducted a study demonstrating that abnormal release of the enzyme arginase leads to a lack of bioavailable arginine,…

SteadyMed’s Trevyent for PAH Completes Human Factors Studies Validating Usability and Safety

Specialized Pharmaceutical Company SteadyMed Ltd. recently announced the completion of its program on human factors studies involving its flagship product candidate, Trevyent (treprostinil sodium), which is currently undergoing testing as a potential new treatment for pulmonary arterial hypertension (PAH). Trevyent is currently the only FDA-approved parenteral treatment for PAH, deliverable…

An Exciting Time for Research into CTEPH Discussed in Review Article

Patients with pulmonary hypertension may be surprised to know that the disease can sometimes be accompanied by the complication known as thromboembolic pulmonary hypertension (CTEPH). Pulmonary embolisms are the root cause of CTEPH because a pulmonary embolism (a blood clot in the lungs) that fails to be degraded via thromboembolysis…

SteadyMed and Cardiome Partner To Commercialize PAH Therapy Trevyent Outside The U.S.

SteadyMed Ltd., a pharmaceutical company developing therapies for both high value and orphan diseases with unmet parenteral delivery needs, and Cardiome Pharma Corp. have recently announced an exclusive agreement for Cardiome to market Trevyent in specific markets outside the United States if Trevyent receives approval to treat pulmonary arterial hypertension (PAH) in those regions. The license agreement stipulates that SteadyMed…

CTEPH Patients Can Develop Coronary-Pulmonary Collateral Vessels, According To Study

Researchers at University of California, San Diego (UCSD) recently published findings in the journal Pulmonary Circulation revealing the prevalence of specific collateral arteries in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The study is entitled “Prevalence of coronary artery-pulmonary artery collaterals in patients with chronic…

Mayo Clinic’s Pulmonary Hypertension Program Nationally Recognized

The Mayo Clinic in Florida has been named as a Pulmonary Hypertension Care Center by the Pulmonary Hypertension Association. This designation is only awarded to centers that can provide early diagnosis, specialized care options and therapies for pulmonary hypertension, as well as follow-up capacities and clinical research projects. The Mayo Clinic now joins the 26 Pulmonary…

Pluristem Therapeutics Receives Australian Patent For Novel Pulmonary Hypertension Therapy Process

Pluristem Therapeutics was recently granted an Australian patent entitled “Adherent Cells From Placenta Tissue and Use Thereof in Therapy,” and was assigned patent number 2009288781 covering Pluristem’s proprietary 3D method to grow cells from both placental or adipose tissue that can be used as treatment for several conditions including pulmonary hypertension. The term of the patent…